Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuati...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2023-07-01
|
| Schriftenreihe: | Clinical and Translational Radiation Oncology |
| Schlagworte: | |
| Online-Zugang: | http://www.sciencedirect.com/science/article/pii/S240563082300068X |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|